- The European Commission (EC) has approved Roche's (OTCQX:RHHBY) Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with Halozyme Therapeutics' (NASDAQ:HALO) ENHANZE technology, administered by subcutaneous injection for the treatment of patients with early and metastatic HER2-positive breast cancer.
- Phesgo has the potential to reduce administration time, as well as other costs associated with treatment, such as time spent in the infusion chair and drug preparation.
- https://seekingalpha.com/news/3646874-roches-phesgo-along-halozymes-enhanze-technology-okd-in-europe-in-breast-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.